Q.10 A vector derived from which one of the following viruses is used for high– frequency genomic integration of a transgene in animal cells?
(A) Adenovirus
(B) Adeno–associated virus
(C) Lentivirus
(D) Herpes simplex virus
Adeno-associated virus (AAV) vectors are used for high-frequency genomic integration of transgenes in animal cells due to their unique site-specific integration at the AAVS1 locus on chromosome 19.
Option Analysis
Adenovirus: Adenovirus vectors excel in high transduction efficiency and transient gene expression but remain primarily episomal without stable genomic integration, making them unsuitable for long-term transgene persistence.
B Adeno-associated virus: AAV integrates efficiently at the AAVS1 site via Rep proteins and non-homologous end-joining, achieving 35-70% integration frequency in cell lines, ideal for stable transgene expression in non-dividing cells.
C Lentivirus: Lentiviral vectors integrate randomly into the host genome via integrase, effective for dividing and non-dividing cells but lacking AAV’s site-specific high-frequency mechanism, with risks of insertional mutagenesis.
D Herpes simplex virus: HSV vectors provide large-capacity episomal persistence for transient expression in neurons but rarely achieve stable genomic integration, limiting their use for permanent transgene delivery.
Adeno-associated virus genomic integration offers unparalleled efficiency for transgene delivery in animal cells, making it the gold standard for long-term gene therapy applications. Unlike other viral vectors, AAV achieves site-specific integration at the AAVS1 locus on chromosome 19q13.4, ensuring stable expression without random mutagenesis risks.
Why AAV Excels in Genomic Integration
AAV vectors transduce both dividing and quiescent cells, with wild-type AAV using Rep proteins for targeted integration, while recombinant forms leverage DNA damage sites via non-homologous end-joining for 50-70% efficiency. This biphasic lifecycle—episomal persistence or chromosomal insertion—supports applications in hepatocytes and fibroblasts.
Viral Vector Comparison
| Vector | Integration Type | Frequency | Key Limitation |
|---|---|---|---|
| Adenovirus | Episomal | Low | Transient expression |
| AAV | Site-specific (AAVS1) | High (35-70%) | Helper virus needed |
| Lentivirus | Random | Moderate | Mutagenesis risk |
| HSV | Episomal | Low | Neuronal focus |
Applications in Gene Therapy
AAV’s safety profile drives its use in clinical trials for neuromuscular diseases, with integration hotspots in active genes enhancing longevity in low-proliferating tissues like liver cells. Ongoing research refines AAV for pain research and oncology via precise transgene insertion.
